Equillium Q2 2026 net loss $4.7M; cash $57.2M funds operations into 2029

Equillium, Inc.

Net loss $4.7M ($0.04/share) vs $5.7M ($0.16/share) in Q2 2025; R&D spend down to $2.8M from $4.1M.
Cash and equivalents $57.2M at June 30, 2026, down from $61.3M at March 31, 2026; runway into 2029.
EQ504 Phase 1 proof-of-mechanism study expected to start Q4 2026; topline data ~6 months later.
IND-enabling work initiated for inhaled EQ504 (lung disease) and oral EQ302 (celiac disease).
Clinical Advisory Board for EQ504 ulcerative colitis program chaired by Prof. Bruce Sands (Mount Sinai).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.